Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

In Vivo Ibrutinib Abrogates BCR-Dependent Adhesion in Tumor Cells of Patients with Chronic Lymphocytic Leukemia

Sarah E. M. Herman, PhD, Rashida Z Mustafa, BS, Mohammed Farooqui, DO, Adrian Wiestner, MD PhD

Blood (2014) 124 (21): 1936.

https://doi.org/10.1182/blood.V124.21.1936.1936

Published: 2014

Journal Articles

Ibrutinib inhibits BCR and NF-κB signaling and reduces tumor proliferation in tissue-resident cells of patients with CLL

Sarah E. M. Herman, Rashida Z. Mustafa, Jennifer A. Gyamfi, Stefania Pittaluga, Stella Chang, Betty Chang, Mohammed Farooqui, Adrian Wiestner

Blood (2014) 123 (21): 3286–3295.

https://doi.org/10.1182/blood-2014-02-548610

Published: 2014

Includes: Supplemental data

Journal Articles

Effective Inhibition Of Tumor Microenvironment Interactions In CLL Patients Treated With The BTK Inhibitor Ibrutinib Results In Sustained Inhibition Of Tumor Proliferation and Survival Pathways

Sarah E. M. Herman, PhD, Rashida Z Mustafa, BS, Sabrina E. Martyr, MD, Jennifer Gyamfi, MS, Janet Valdez, PA, Susan Soto, RN, Mohammed Farooqui, DO, Adrian Wiestner, MD, PhD

Blood (2013) 122 (21): 118.

https://doi.org/10.1182/blood.V122.21.118.118

Published: 2013

Journal Articles

In Vivo Effects Of Ibrutinib On The Migration Of Chronic Lymphocytic Leukemia Cells Differ Between Patients and Reduce The Ability Of The Bone Marrow Microenvironment To Attract The Tumor Cells

Sarah E. M. Herman, PhD, Jade Jones, Rashida Z. Mustafa, BS, Mohammed Farooqui, DO, Adrian Wiestner, MD, PhD

Blood (2013) 122 (21): 604.

https://doi.org/10.1182/blood.V122.21.604.604

Published: 2013

Journal Articles

Ibrutinib Inhibits B-Cell Adhesion and Causes An Efflux Of Chronic Lymphocytic Leukemia Cells From The Tissue Microenvironment Into The Blood Leading To a Transient Treatment-Induced Lymphocytosis

Rashida Z Mustafa, BS, Sarah E. M. Herman, PhD, Jade Jones, Jennifer Gyamfi, MS, Mohammed Farooqui, DO, Adrian Wiestner, MD, PhD

Blood (2013) 122 (21): 674.

https://doi.org/10.1182/blood.V122.21.674.674

Published: 2013

NARROW

In Vivo Ibrutinib Abrogates BCR-Dependent Adhesion in Tumor Cells of Patients with Chronic Lymphocytic Leukemia

Ibrutinib inhibits BCR and NF-κB signaling and reduces tumor proliferation in tissue-resident cells of patients with CLL

Effective Inhibition Of Tumor Microenvironment Interactions In CLL Patients Treated With The BTK Inhibitor Ibrutinib Results In Sustained Inhibition Of Tumor Proliferation and Survival Pathways

In Vivo Effects Of Ibrutinib On The Migration Of Chronic Lymphocytic Leukemia Cells Differ Between Patients and Reduce The Ability Of The Bone Marrow Microenvironment To Attract The Tumor Cells

Ibrutinib Inhibits B-Cell Adhesion and Causes An Efflux Of Chronic Lymphocytic Leukemia Cells From The Tissue Microenvironment Into The Blood Leading To a Transient Treatment-Induced Lymphocytosis

Email alerts

ASH Publications

American Society of Hematology

In Vivo Ibrutinib Abrogates BCR-Dependent Adhesion in Tumor Cells of Patients with Chronic Lymphocytic Leukemia

Ibrutinib inhibits BCR and NF-κB signaling and reduces tumor proliferation in tissue-resident cells of patients with CLL

Effective Inhibition Of Tumor Microenvironment Interactions In CLL Patients Treated With The BTK Inhibitor Ibrutinib Results In Sustained Inhibition Of Tumor Proliferation and Survival Pathways

In Vivo Effects Of Ibrutinib On The Migration Of Chronic Lymphocytic Leukemia Cells Differ Between Patients and Reduce The Ability Of The Bone Marrow Microenvironment To Attract The Tumor Cells

Ibrutinib Inhibits B-Cell Adhesion and Causes An Efflux Of Chronic Lymphocytic Leukemia Cells From The Tissue Microenvironment Into The Blood Leading To a Transient Treatment-Induced Lymphocytosis

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only